The Parkinson’s Protocol – Natural Healing By Jodi Knapp. Clear Step by Step Instructions – Get The Parkinson’s Protocol For an Exclusive Discounted Price. Get it today (Recommended)
Source: The Parkinson’s Protocol™ By Jodi Knapp — Parkinsons Protocol by Jodi Knapp
Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Therapeutic Effects of Hydrogen in Animal Models of Parkinson’s Disease
Source: Therapeutic Effects of Hydrogen in Animal Models of Parkinson’s Disease – PMC
https://youtube.com/RpMEMX-c7VU?t=7
We reviewed computerized tomograms (CT) for basal ganglia and dentate nucleus calcifications in 79 patients with Parkinson’s disease (PD), 54 patients with Alzheimer’s disease (AD) and 109 controls aged 50 or more. When it was determined, no patient had disturbances in calcium metabolism. We found: …
92 patients with Parkinson’s disease not previously treated with levodopa were considered as eligible for this triple-blind trial. Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules …
Source: Parkinson’s disease treated with Sinemet or Madopar. A controlled multicenter trial – PubMed
One recently published clinical study tested the effects of the ketogenic diet on symptoms of Parkinson’s disease (VanItallie et al., 2005). In this uncontrolled study, Parkinson’s disease patients experienced a mean of 43% reduction in Unified Parkinson’s Disease Rating Scale scores after a 28-day exposure to the ketogenic diet. All participating patients reported moderate to very good improvement in symptoms. Further, as in Alzheimer’s disease, consumption of foods containing increased amounts of essential fatty acids has been associated with a lower risk of developing Parkinson’s disease (de Lau et al., 2005).
Source: Neuroprotective and disease-modifying effects of the ketogenic diet – PMC
see more video’s with Datis in youtube, dealing with gut-brain connection, microbiome, vegas nerve etc.
Datis suggest among other things:
excersise , intensive short (intervals ? for the brain )
bioflavonoids ( colorful fruit and vegetables
practicing stuff you are not good at
Glutathione as it does so many things
mind your nitric oxide levels
His website
Book
Studies in mice reveal that intake of a ketogenic diet or exogenous ketone bodies may alleviate lymphedema by increasing the formation of lymphatic vessels, which can drain excess lymph fluid.
www.nature.com/articles/s42255-019-0090-3
Glutamine effectively increases circulating GLP-1, GIP and insulin levels in vivo and may represent a novel therapeutic approach to stimulating insulin secretion in obesity and type 2 diabetes.
Keywords: GLP-1, GIP, glucagon, insulin secretion, glutamine
This clip is by Swiss medica clinic
youtu.be/n6yxkFl0olk
#q1 how this works with downers
they treat aa range of auto-immune conditions
say they helped 145 people
Source: Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson’s Disease
Background: In moderately advanced Parkinson’s disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD.
Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression.
Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, 
, and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change.
Results: At baseline, 13% had borderline low B12 levels, 7% had elevated homocysteine, whereas 2% had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability. © 2018 International Parkinson and Movement Disorder Society Supporting Informatio
People who take immunosuppressants less likely to develop the disease
Prednison and other immunosuppressant effective for pre and early stage PD
